Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Totum-63 Effect on Glucose and Lipid Homeostasis in People With Abdominal Obesity Associated With Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia

NCT02868177 is registered in ClinicalTrials.gov with Valbiotis as lead sponsor.

NCT NCT02868177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02868177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Totum-63 Effect on Glucose and Lipid Homeostasis in People With Abdominal Obesity Associated With Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia
Lead sponsor
Valbiotis
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2016
Completion date
April 30, 2019
Enrollment
66 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

disease, hypertriglyceridemia, insulin resistance, obesity, prediabetes, type 2 diabetes